r 348

JAK-IN-11 (R-348) is a potent and selective inhibitor of JAK, has the potential for the skin disorders treatment.

Pralnacasan inhibits proinflammatory cytokines IL-18, IL-1β , and IFN-γ. Pralnacasan is an effective, non-peptide, and orally active interleukin-1β converting enzyme inhibitor (Ki: 1.4 nM). Pralnacasan has the potential for osteoarthritis and rheumatoid a

SAR348830 is an ALK inhibitor, targeting anaplastic lymphoma kinase.

Etibendazole is a microtubule inhibitor.

Compound 7a, (Z)-(1R,3R,4R,4aS,8R,8aR)-3,4,8,8a-tetramethyl-7-oxo-4-(2-(5-oxo-2,5-dihydrofuran-3-yl)ethyl)decahydronaphthalen-1-yl 2-methylbut-2-enoate, is a clerodane diterpene [1].

Mitapivat (AG-348) hydrochloride is an orally active and selective allosteric activator of pyruvate kinase R (PK-R). It enhances the PK-R-catalyzed conversion of phosphoenolpyruvate to pyruvate, thereby promoting the glycolysis pathway, increasing ATP production in red blood cells, and decreasing 2,3-diphosphoglycerate (2,3-DPG) levels. Mitapivat hydrochloride is being investigated for potential use in the study of pyruvate kinase deficiency and other anemia-related disorders.

R-932348 choline, a dual JAK/SYK inhibitor, is used potentially for treatment of dry eye disease.